Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a buy rating to a strong-buy rating in a report released on Saturday,Wall Street Zen reports.

Several other equities analysts have also commented on the stock. Weiss Ratings raised shares of Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Jefferies Financial Group raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Friday, September 25th. Finally, Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.23.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $4.39 on Friday. The firm has a market cap of $725.40 million, a P/E ratio of 4.88 and a beta of 0.25. The stock has a 50 day simple moving average of $3.91 and a two-hundred day simple moving average of $3.97. Ironwood Pharmaceuticals has a 1 year low of $1.88 and a 1 year high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.04. The business had revenue of $133.04 million for the quarter, compared to analysts’ expectations of $119.99 million. Ironwood Pharmaceuticals had a net margin of 37.38% and a negative return on equity of 81.40%. On average, equities analysts anticipate that Ironwood Pharmaceuticals will post 1.10 earnings per share for the current year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. purchased a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth about $40,000. Y Intercept Hong Kong Ltd purchased a new position in Ironwood Pharmaceuticals during the 1st quarter valued at about $47,000. Bull Harbor Capital LLC purchased a new position in Ironwood Pharmaceuticals during the 1st quarter valued at about $48,000. Ascent Group LLC bought a new position in Ironwood Pharmaceuticals during the 3rd quarter valued at approximately $58,000. Finally, DGS Capital Management LLC raised its position in Ironwood Pharmaceuticals by 42.8% during the 1st quarter. DGS Capital Management LLC now owns 14,883 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 4,458 shares during the last quarter.

Key Ironwood Pharmaceuticals News

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Ironwood reported Q3 adjusted earnings of $0.36 per share, above analyst expectations, while net income rose 49% year over year. It raised 2026 revenue guidance to $485 million–$510 million, above the roughly $470.5 million consensus, and increased its EBITDA outlook. Management also cited stronger Linzess sales expectations and profitability. Ironwood Q3 net income rises and outlook increases
• Neutral Sentiment: Revenue commentary was inconsistent: one Zacks headline described revenue as missing expectations, while reported figures of $133.04 million exceeded the estimate of $119.99 million cited elsewhere. Zacks Q3 earnings and outlook coverage

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood’s principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.